Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nantakarn Pongtarakulpanit

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Lupus Science & Medicine|November 3, 2020
Efficacy and safety of rituximab biosimilar in refractory lupusNantakarn Pongtarakulpanit, Prapaporn Pisitkun, Pintip Ngamjanyaporn
BMC Rheumatology|August 19, 2025
Clinical characteristics and outcomes of anti-MDA5 dermatomyositis: a retrospective studyTulaton Sodsri, Tananchai Petnak, Thitiporn Suwatanapongched, et al.
Clinical and Experimental Rheumatology|November 6, 2025
Dermatomyositis assessment of rash via telemedicine: a prospective studyNantakarn Pongtarakulpanit, Anuradha Bishnoi, Dana P Ascherman, et al.
Clinical Rheumatology|August 26, 2024
Internet-based enrollment of a myositis patient cohort-a national experienceRaisa Lomanto Silva, Shiri Keret, Tanya Chandra, et al.
Rheumatology (Oxford, England)|August 29, 2024
Disease characteristics and medications use in idiopathic inflammatory myopathy: a multi-centre prospective observational study of decentralized remote vs. traditional clinic enrolmentShiri Keret, Raisa Lomanto Silva, Tanya Chandra, et al.
Clinical and Experimental Rheumatology|December 2, 2025
Health-related quality of life improvements and response thresholds of myositis outcome measures and response criteriaMaha Almackenzie, Anushka Aggarwal, Shiri Keret, et al.
Therapeutics and Clinical Risk Management|December 29, 2025
Prognostic Factors and Clinical Prediction Score for Progressive Respiratory Failure in Severe COVID-19 Pneumonia Patients Treated with Tocilizumab: A Multicenter StudyNantakarn Pongtarakulpanit, Kulapong Jayanama, Phichayut Phinyo, et al.
The Journal of Rheumatology|April 15, 2026
Remission rates and predictors in idiopathic inflammatory myopathy subgroups: Insights from a single-center cohortNantakarn Pongtarakulpanit, Sidra Tahir, Varshapriya Suresh, et al.
Rheumatology (Oxford, England)|April 25, 2025
Short Form-36 psychometric properties in idiopathic inflammatory myopathies: reliability, validity, and responsivenessShiri Keret, Anushka Aggarwal, Maha Almackenzie, et al.
Rheumatology (Oxford, England)|April 23, 2025
Recruitment rate comparison between a virtual tele-research cohort and a traditional center-based cohort in idiopathic inflammatory myopathySiamak Moghadam-Kia, Anushka Aggarwal, Swamy Venuturupalli, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Lupus Science & Medicine|November 3, 2020
Efficacy and safety of rituximab biosimilar in refractory lupusNantakarn Pongtarakulpanit, Prapaporn Pisitkun, Pintip Ngamjanyaporn
BMC Rheumatology|August 19, 2025
Clinical characteristics and outcomes of anti-MDA5 dermatomyositis: a retrospective studyTulaton Sodsri, Tananchai Petnak, Thitiporn Suwatanapongched, et al.
Clinical and Experimental Rheumatology|November 6, 2025
Dermatomyositis assessment of rash via telemedicine: a prospective studyNantakarn Pongtarakulpanit, Anuradha Bishnoi, Dana P Ascherman, et al.
Clinical Rheumatology|August 26, 2024
Internet-based enrollment of a myositis patient cohort-a national experienceRaisa Lomanto Silva, Shiri Keret, Tanya Chandra, et al.
Rheumatology (Oxford, England)|August 29, 2024
Disease characteristics and medications use in idiopathic inflammatory myopathy: a multi-centre prospective observational study of decentralized remote vs. traditional clinic enrolmentShiri Keret, Raisa Lomanto Silva, Tanya Chandra, et al.
Clinical and Experimental Rheumatology|December 2, 2025
Health-related quality of life improvements and response thresholds of myositis outcome measures and response criteriaMaha Almackenzie, Anushka Aggarwal, Shiri Keret, et al.
Therapeutics and Clinical Risk Management|December 29, 2025
Prognostic Factors and Clinical Prediction Score for Progressive Respiratory Failure in Severe COVID-19 Pneumonia Patients Treated with Tocilizumab: A Multicenter StudyNantakarn Pongtarakulpanit, Kulapong Jayanama, Phichayut Phinyo, et al.
The Journal of Rheumatology|April 15, 2026
Remission rates and predictors in idiopathic inflammatory myopathy subgroups: Insights from a single-center cohortNantakarn Pongtarakulpanit, Sidra Tahir, Varshapriya Suresh, et al.
Rheumatology (Oxford, England)|April 25, 2025
Short Form-36 psychometric properties in idiopathic inflammatory myopathies: reliability, validity, and responsivenessShiri Keret, Anushka Aggarwal, Maha Almackenzie, et al.
Rheumatology (Oxford, England)|April 23, 2025
Recruitment rate comparison between a virtual tele-research cohort and a traditional center-based cohort in idiopathic inflammatory myopathySiamak Moghadam-Kia, Anushka Aggarwal, Swamy Venuturupalli, et al.
Pageof 2